Literature DB >> 12695191

Pre- and post-treatment MR imaging and single photon emission CT in patients with dural arteriovenous fistulas and retrograde leptomeningeal venous drainage.

Yutaka Kai1, Jun-ichiro Hamada, Motohiro Morioka, Tatemi Todaka, Takamasa Mizuno, Yukitaka Ushio.   

Abstract

BACKGROUND AND
PURPOSE: Dural arteriovenous fistulas (DAVFs) with disturbed regional cerebral blood flow (rCBF) include retrograde leptomeningeal venous drainage (RLVD). We examined rCBF disturbances in patients with DAVFs by studying MR imaging and single photon emission CT (SPECT) changes before and after treatment.
METHODS: In 22 patients with DAVFs and RLVD, we studied their symptoms, pre- and post-treatment MR imaging and SPECT findings, and treatment results. Patients were assigned to two groups: Type 1 included those with RLVD into more than one venous sinus, and type 2, those with RLVD into a single venous sinus.
RESULTS: Eleven patients had type 1 RLVD. In these patients, preoperative T2-weighted MR images showed no hyperintense areas, and angiographic evidence showed flow into more than one venous sinus. The other 11 patients had type 2 RLVD. In these patients, preoperative SPECT demonstrated hypoperfused areas that coincided with hyperintense areas on T2-weighted MR images. After treatment, the hyperintense areas disappeared, and symptoms improved in seven of these patients (type 2a). Their preoperative SPECT studies demonstrated preservation of vasoreactivity after an acetazolamide challenge. In the other four patients (Type 2b), the hyperintense areas and symptoms persisted after treatment. Their preoperative SPECT studies revealed a marked disturbance of vasoreactivity.
CONCLUSION: In patients with drainage into a single venous sinus, we consistently observed areas of hyperintensity on MR images. These results and findings of hypoperfusion on SPECT scans apparently reflect venous congestion, whereas unpreserved vasoreactivity after an acetazolamide challenge on SPECT scans reflects venous infarction. The preservation of vasoreactivity after the challenge appears to be a good prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695191      PMCID: PMC8148660     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  19 in total

1.  Histopathological study of venous aneurysms in patients with dural arteriovenous fistulas.

Authors:  J Hamada; S Yano; Y Kai; K Koga; M Morioka; Y Ishimaru; Y Ushio
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Embolization with cellulose porous beads, II: Clinical trial.

Authors:  J Hamada; Y Kai; S Nagahiro; N Hashimoto; H Iwata; Y Ushio
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

3.  Embolization with cellulose porous beads, I: An experimental study.

Authors:  J Hamada; Y Ushio; K Kazekawa; T Tsukahara; N Hashimoto; H Iwata
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

4.  Surgical interruption of leptomeningeal drainage as treatment for intracranial dural arteriovenous fistulas without dural sinus drainage.

Authors:  M Collice; G D'Aliberti; G Talamonti; V Branca; E Boccardi; G Scialfa; P P Versari
Journal:  J Neurosurg       Date:  1996-05       Impact factor: 5.115

5.  Treatment of cranial dural arteriovenous fistulae by interruption of leptomeningeal venous drainage.

Authors:  B G Thompson; J L Doppman; E H Oldfield
Journal:  J Neurosurg       Date:  1994-04       Impact factor: 5.115

6.  Correlation between magnetic resonance images and draining patterns in dural arteriovenous fistulas with leptomeningeal venous drainage.

Authors:  Y Kai; J Hamada; M Morioka; K Koga; S Hasegawa; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

7.  Postoperative hyperperfusion in dural arteriovenous fistula associated with venous ischemia: case report.

Authors:  S Kuroda; S Ushikoshi; K Houkin; H Saito; Y Kikuchi; H Abe
Journal:  Surg Neurol       Date:  1998-04

8.  Dementia resulting from dural arteriovenous fistulas: the pathologic findings of venous hypertensive encephalopathy.

Authors:  R W Hurst; L J Bagley; S Galetta; G Glosser; A P Lieberman; J Trojanowski; G Sinson; M Stecker; E Zager; E C Raps; E S Flamm
Journal:  AJNR Am J Neuroradiol       Date:  1998-08       Impact factor: 3.825

9.  A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment.

Authors:  J A Borden; J K Wu; W A Shucart
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

10.  Hemodynamics before and after the total removal of a dural arteriovenous malformation of the posterior fossa. Case report.

Authors:  T Kawaguchi; S Fujita; H Yamada; Y Nishida; E Mori
Journal:  Surg Neurol       Date:  1988-12
View more
  4 in total

1.  Hemodynamic studies of intracranial dural arteriovenous fistulas using arterial spin-labeling MR imaging.

Authors:  T Noguchi; H Irie; Y Takase; M Kawashima; T Ootsuka; M Nishihara; Y Egashira; J Nojiri; T Matsushima; S Kudo
Journal:  Interv Neuroradiol       Date:  2010-12-17       Impact factor: 1.610

Review 2.  Arteriovenous fistulas at the cervicomedullary junction presenting with subarachnoid hemorrhage: six case reports with special reference to the angiographic pattern of venous drainage.

Authors:  Yutaka Kai; Jun-ichiro Hamada; Motohiro Morioka; Shigetoshi Yano; Takamasa Mizuno; Jun-ichi Kuratsu
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

3.  Subcortical calcification on CT in dural arteriovenous fistula with cortical venous reflux.

Authors:  T Metoki; S Mugikura; S Higano; M Ezura; Y Matsumoto; K Hirayama; S Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

4.  Multiple dural arteriovenous fistulas causing rapid progressive dementia successfully treated by endovascular surgery: case report.

Authors:  Kazuhiro Abe; Osamu Okuda; Hidenori Ohishi; Makoto Sonobe; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-20       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.